Companion Diagnostics - CDx Summit
26-27

November 2015

Germany

Berlin

NH Collection Berlin Friedrichstrasse Hotel

Friedrichstrasse 96, 10117

About

This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics. Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This year, for the first time, the companion diagnostic community will meet to analyse and tackle the latest and greatest opportunities i...

This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics. Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This year, for the first time, the companion diagnostic community will meet to analyse and tackle the latest and greatest opportunities in the CDx. In this Summit you will learn more about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

more info
Who Should Attend

CEOs, Companion Diagnostics Vice-Presidents, Directors, Chief Medical Officers from:

  • Companion Diagnostics
  • Worldwide Regulatory Strategy
  • Biomarkers
  • Medical Sciences
  • Principal Scientist
  • Corporate Development & Ventures
  • Global Diagnostic
  • Companion Diagnostic Development
  • Regulatory Affairs
  • Companion Diagnostic Development
  • Diagnostic & Experimental Pathology

From Industries Including: 

  • Pharmaceutical
  • Research Institutes
  • Biotechnology
  • CD entities
Key Practical Learning Points of the Summit

The latest trends of companion diagnostics (CDx) development
Partnering strategies to achieve successful commercialization of CDx
Manufacture CDx at the anticipated scale
Pharmaceutical and Diagnostics Companies Perspectives
CDx development and pre-launch commercialization costs
Finding the appropriate business models for CDx companies
The laboratory developed test (LDT) & In vitro diagnostic (IVD) Models
Introduction of a strategy that can improve the existing models
Speakers
Dr. Bruce W. M. Jordan

VP, International Business Leader Companion Diagnostics

Roche Diagnostics

Dr. Maria Orr

Executive Director & Lead of Companion Diagnostics (Oncology Phase III/Development for Launch Asset)

AstraZeneca

Dr. David Atkins

Vice President

Leica Biosystems

Dr. Ian Miller

Founder

Healthcare Strategies Group

Dr. Eddie Blair

Managing Director

Integrated Medicines Ltd.

Dr. Philipp Angenendt

Director of Pharmaceutical Sales and Technology

Sysmex Inostics

Dr. Tero Laulajainen

VP ClinOps

Roche Professional Diagnostics

Susanne Munksted

Global Commercial Director

Agilent Technologies

Prof. Arndt Rolfs

Chief Executive Officer

Centogene AG

Robert Loewe

Companion Diagnostics R-Biopharm AG, Darmstadt Companion Diagnostics

Annual

Events

Sponsors and Partners

Sponsor

Media partner

Media partner

Media partner

Media partner

Media partner